ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,281 to 2,300 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Sepsis Transition and Recovery (STAR) Program vs Usual Care: Discharge to Hospice Care97 of 2,122

69 of 1,426

-0.3 points

-1.7 to 1.1

3,548NCT04495946

Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship

Sepsis Transition and Recovery (STAR) Program vs Usual Care: serious adverse events763 of 2,122

478 of 1,426

2.4 points

-0.8 to 5.6

3,548NCT04495946

Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship

Vadadustat vs Darbepoetin Alfa: deaths from any cause276 of 1,768

290 of 1,769

-0.8 points

-3.2 to 1.6

3,537NCT02892149

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Vadadustat vs Darbepoetin Alfa: serious adverse events973 of 1,768

1,032 of 1,769

-3.3 points

-6.6 to -0.0

3,537NCT02892149

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Vacc-039 Group vs Vacc-092 Group: serious adverse events0 of 1,671

1 of 1,866

-0.1 points

-0.3 to 0.2

3,537NCT03629886

Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study

Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of Initiation of Chronic Renal Replacement Therapy87 of 1,767

100 of 1,766

-0.7 points

-2.2 to 0.7

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Acute Myocardial Infarction (Non Fatal); Non-fatal Stroke; and CV Death212 of 1,767

254 of 1,766

-2.4 points

-4.6 to -0.2

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of CV Death123 of 1,767

169 of 1,766

-2.6 points

-4.4 to -0.8

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of Onset of Persistent ≥50% Reduction in eGFR (CKD-EPI)165 of 1,767

213 of 1,766

-2.7 points

-4.8 to -0.7

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to First Occurrence of Major Adverse Limb Events (MALE): Acute Limb Ischaemia Hospitalization and Chronic Limb Ischaemia Hospitalization16 of 1,767

28 of 1,766

-0.7 points

-1.5 to 0.1

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of Renal Death5 of 1,767

5 of 1,766

-0.0 points

-0.4 to 0.4

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to Occurrence of Each of the Individual Components of the Confirmatory Secondary MACE Endpoint: Non-fatal Myocardial Infarction52 of 1,767

64 of 1,766

-0.7 points

-1.9 to 0.5

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Semaglutide vs Placebo: Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death331 of 1,767

410 of 1,766

-4.5 points

-7.2 to -1.8

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of Onset of Persistent eGFR (CKD-EPI) <15mL/Min/1.73m^292 of 1,767

110 of 1,766

-1.0 points

-2.6 to 0.5

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to Occurrence of Each of the Individual Components of the Confirmatory Secondary MACE Endpoint: Non-fatal Stroke63 of 1,767

51 of 1,766

0.7 points

-0.5 to 1.9

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to Occurrence of All-cause Death227 of 1,767

279 of 1,766

-3.0 points

-5.3 to -0.6

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Semaglutide vs Placebo: deaths from any cause227 of 1,767

279 of 1,766

-3.0 points

-5.3 to -0.6

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Semaglutide vs Placebo: serious adverse events877 of 1,767

950 of 1,766

-4.2 points

-7.4 to -0.9

3,533NCT03819153

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Intervention vs Control: deaths from any cause5 of 1,749

2 of 1,783

0.2 points

-0.2 to 0.6

3,532NCT01849575

Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention

Novartis MenACWY Vaccine vs Licensed Meningococcal Vaccine: Number of Participants With at Least One Severe Systemic Reaction, Ages 11 to 55 Years94 of 2,649

24 of 875

0.8 points

-0.6 to 2.0

3,524NCT00450437

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=115"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=115

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04495946-f32dda21",
        "title": "Sepsis Transition and Recovery (STAR) Program vs Usual Care: Discharge to Hospice Care",
        "summary": "97 of 2122 against 69 of 1426; risk difference -0.3 points, 95% interval -1.7 to 1.1; NCT04495946, Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship",
        "record": "/library/comparisons/NCT04495946-f32dda21",
        "nct_id": "NCT04495946",
        "kind": "outcome",
        "participants": 3548,
        "risk_difference": {
          "value": -0.0026755039372472686,
          "lower": -0.017485557930330006,
          "upper": 0.011264199868233559
        },
        "group_1": "97 of 2,122",
        "group_2": "69 of 1,426",
        "difference": "-0.3 points",
        "interval": "-1.7 to 1.1",
        "trial_title": "Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship"
      },
      {
        "id": "NCT04495946-sae",
        "title": "Sepsis Transition and Recovery (STAR) Program vs Usual Care: serious adverse events",
        "summary": "763 of 2122 against 478 of 1426; risk difference 2.4 points, 95% interval -0.8 to 5.6; NCT04495946, Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship",
        "record": "/library/comparisons/NCT04495946-sae",
        "nct_id": "NCT04495946",
        "kind": "serious-adverse-events",
        "participants": 3548,
        "risk_difference": {
          "value": 0.02436308068944454,
          "lower": -0.007678324573120655,
          "upper": 0.05604934806473098
        },
        "group_1": "763 of 2,122",
        "group_2": "478 of 1,426",
        "difference": "2.4 points",
        "interval": "-0.8 to 5.6",
        "trial_title": "Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=116",
  "request_id": "Ow4CoLdz83XFdjjT"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?